Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

508 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Inferring epidemic contact structure from phylogenetic trees.
Leventhal GE, Kouyos R, Stadler T, Wyl Vv, Yerly S, Böni J, Cellerai C, Klimkait T, Günthard HF, Bonhoeffer S. Leventhal GE, et al. Among authors: yerly s. PLoS Comput Biol. 2012;8(3):e1002413. doi: 10.1371/journal.pcbi.1002413. Epub 2012 Mar 8. PLoS Comput Biol. 2012. PMID: 22412361 Free PMC article.
A prospective trial of structured treatment interruptions in human immunodeficiency virus infection.
Fagard C, Oxenius A, Günthard H, Garcia F, Le Braz M, Mestre G, Battegay M, Furrer H, Vernazza P, Bernasconi E, Telenti A, Weber R, Leduc D, Yerly S, Price D, Dawson SJ, Klimkait T, Perneger TV, McLean A, Clotet B, Gatell JM, Perrin L, Plana M, Phillips R, Hirschel B; Swiss HIV Cohort Study. Fagard C, et al. Among authors: yerly s. Arch Intern Med. 2003 May 26;163(10):1220-6. doi: 10.1001/archinte.163.10.1220. Arch Intern Med. 2003. PMID: 12767960 Free article.
HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss.
Schüpbach J, Günthard H, Joos B, Fischer M, Böni J, Tomasik Z, Yerly S, Perrin L, Battegay M, Furrer H, Vernazza P, Bernasconi E, Hirschel B; Swiss HIV Cohort Study. Schüpbach J, et al. Among authors: yerly s. J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):250-6. doi: 10.1097/01.qai.0000181281.75670.56. J Acquir Immune Defic Syndr. 2005. PMID: 16249697 Clinical Trial.
Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types.
von Wyl V, Yerly S, Böni J, Bürgisser P, Klimkait T, Battegay M, Furrer H, Telenti A, Hirschel B, Vernazza PL, Bernasconi E, Rickenbach M, Perrin L, Ledergerber B, Günthard HF; Swiss HIV Cohort Study. von Wyl V, et al. Among authors: yerly s. Arch Intern Med. 2007 Sep 10;167(16):1782-90. doi: 10.1001/archinte.167.16.1782. Arch Intern Med. 2007. PMID: 17846398
Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir.
von Wyl V, Yerly S, Böni J, Bürgisser P, Klimkait T, Battegay M, Bernasconi E, Cavassini M, Furrer H, Hirschel B, Vernazza PL, Rickenbach M, Ledergerber B, Günthard HF; Swiss HIV Cohort Study. von Wyl V, et al. Among authors: yerly s. Clin Infect Dis. 2008 Apr 15;46(8):1299-309. doi: 10.1086/528863. Clin Infect Dis. 2008. PMID: 18444871 Free article.
508 results